The HbA1c testing market presents opportunities driven by rising Type 2 diabetes cases and advancements in testing ...

Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that ...

According to Nova One Advisor, the global immunoassays market size is calculated at USD 28.51 billion in 2025 and is expected ...

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement ...

Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

The firm is projecting a gradual recovery of the academic market in the face of ongoing funding uncertainties and a government shutdown.